Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Revenue projections:

RVTY's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio	1.800000
forwardPE	26.246813
debtToEquity	46.225000
earningsGrowth	0.012000
revenueGrowth	0.013000
grossMargins	0.549760
operatingMargins	0.170530
trailingEps	2.090000
forwardEps	5.894430

Revvity, Inc.'s current ratio of 1.8, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as Revvity, Inc. has enough cash and current assets to handle its immediate liabilities comfortably.
RVTY's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
RVTY's negative gross and operating margins indicate the company is operating at a loss, unable to generate profit from its core business activities. This suggests financial strain and potential challenges in maintaining profitability.
Revvity, Inc.'s forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that Revvity, Inc. is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

The steady upward revision of RVTY's price projections indicates growing confidence in the company's future. Analysts are increasingly optimistic about RVTY's potential to deliver strong results and increased market value.

Insider Transactions:

8 RVTY transactions were recorded, when the market price was 104.12499904632568.There were no sell transactions throughout the period under consideration.The recent buying activity at current Revvity, Inc. price levels exceeds selling, suggesting a potential positive outlook. Investors may see this trend as an indicator that the stock is likely to perform well, reflecting growing confidence.

Recommendation changes over time:

Analysts have been favoring Revvity, Inc. with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning Revvity, Inc. as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.